Vincristine exhibited cytotoxicity against human leukemic MOLT-4 cells, with an IC50 of 3.3 nM at 48 h measured by MTT assay. Continuous incubation of bone marrow from wild-type animals with Vincristine at 100 ng ml−1 reduced colony numbers by more than 90% relative to control wells without the drug. In MOLT-4 cells, Vincristine alone at 3 nM was insufficient to affect mitochondrial membrane potential at 12, 24, 36, and 48 h. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Vincristine cytotoxicity in human leukemic cells
Cell-based study · human leukemic MOLT-4 cells [1]
Human leukemic MOLT-4 cells were treated with various concentrations of vincristine for 48 h, and viability was measured by MTT assay. Vincristine exhibited cytotoxicity with an IC50 of 3.3 nM.
Literature-Reported Treatment Conditions
- Treatment concentration
- various concentrations
- Exposure duration
- 48 h
- Vehicle
- DMSO (dimethylsulfoxide)
- Reported limits
- Not stated in the sentences used: route, control.
Methods and source locations
Compound reported in the paper: Vincristine
The paper names Vincristine without stating the salt or form; not verified as the sulfate form supplied as A10973. No dose conversion or lot validation.
Results > Cytotoxic effects of vincristine and SAHA, alone and in combination, on human leukemic MOLT-4 cells (S5); Methods > Chemicals and antibodies (S69); Methods > Cell viability assay (S75); Fig. 1 legend (S126)
Cell viability was measured by MTT assay: Cell viability was measured by MTT assay — Results > Cytotoxic effects of vincristine and SAHA, alone and in combination, on human leukemic MOLT-4 cells (S5); Fig. 1 legend (S126)
Vincristine reduces bone marrow colony formation
Cell-based study · bone marrow of wild-type animals [2]
Bone marrow of wild-type animals was incubated continuously with Vincristine at 100 ng ml−1. Colony numbers were reduced by more than 90% relative to control wells without the drug.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 ng ml−1
- Exposure duration
- Colonies were scored by day 5.
- Method
- incubated continuously
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Vincristine
The paper names Vincristine without stating the salt or form; not verified as the sulfate form supplied as A10973. No dose conversion or lot validation.
RESULTS (S39); Table 1 legend (S104, S105, S106); Table 1 (T1.h1, T1.r1)
number of colonies: number of colonies; comparator: control wells without the drug — Table 1 legend (S104, S106); Table 1 (T1.h1, T1.r1)
Mitochondrial membrane potential following Vincristine treatment
Cell-based study · MOLT-4 cells [1]
MOLT-4 cells were treated with Vincristine alone at 3 nM. Treatment was insufficient to affect mitochondrial membrane potential at 12, 24, 36, and 48 h.
Literature-Reported Treatment Conditions
- Treatment concentration
- 3 nM
- Exposure duration
- 12, 24, 36, and 48 h
- Vehicle
- DMSO (dimethylsulfoxide)
- Reported limits
- Not stated in the sentences used: route, control.
Methods and source locations
Compound reported in the paper: Vincristine
The paper names Vincristine without stating the salt or form; not verified as the sulfate form supplied as A10973. No dose conversion or lot validation.
Results > Effects of SAHA in combination with vincristine on the apoptotic pathway and HDAC activity in human leukemic MOLT-4 cells (S37); Methods > Chemicals and antibodies (S69); Fig. 4 legend (S145, S146)
mitochondrial membrane potential: mitochondrial membrane potential — Results > Effects of SAHA in combination with vincristine on the apoptotic pathway and HDAC activity in human leukemic MOLT-4 cells (S37); Fig. 4 legend (S145, S146)